Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.
HER2-positive Breast Cancer
DRUG: Capecitabine
disease free survival(DFS), To determine the percentage of disease-free survival (DFS) for the capecitabine monotherapy arm or placebo arm., 5 years
overall survival(OS), To determine the percentage of disease-free survival (DFS) for the capecitabine monotherapy arm or placebo arm., 5 years|medicine safety, To determine the percentage of disease-free survival (DFS) for the capecitabine monotherapy arm or placebo arm., 5 years
This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.